{
  "source": "PA-Med-Nec-Nourianz.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2181-6\nProgram Prior Authorization/Medical Necessity\nMedication Nourianz® (istradefylline)\nP&T Approval Date 12/2019, 12/2020, 12/2021, 12/2022, 12/2023, 12/2024\nEffective Date 3/1/2025\n1. Background:\nNourianz (istradefylline) is indicated as adjunctive treatment to levodopa/carbidopa in adult\npatients with Parkinson’s disease experiencing “off” episodes\nCoverage will be provided for members who meet the following criteria.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Nourianz will be approved based on ALL of the following criteria:\na. Diagnosis of Parkinson’s disease\n-AND-\nb. Used as adjunctive treatment to levodopa/carbidopa in patients experiencing “off”\nepisodes\n-AND-\nc. History of failure, contraindication, or intolerance to two anti-Parkinson’s disease\ntherapy from the following adjunctive pharmacotherapy classes (trial must be from\ntwo different classes):\n(1) Dopamine agonists (e.g., pramipexole, ropinirole)\n(2) Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)\n(3) Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Nourianz will be approved based on BOTH of the following criterion:\na. Documentation of positive clinical response to Nourianz therapy\n-AND-\nb. Patient will continue to receive treatment with a carbidopa/levodopa-containing\n© 2024 UnitedHealthcare Services, Inc.\n1\nmedication\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and r",
    "ge Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n4. References:\n1. Nourianz [package insert]. Bedminster; NJ: Kyowa Kirin, Inc; March 2023.\n2. Liang, T. Medical management of motor fluctuations and dyskinesia in Parkinson\ndisease. In: UpToDate, Hurtig HI (ed). UpToDate. Waltham, MA. Accessed September\n2023.\n3. Fox, SH, Katzenschlager, R, Lim S, et. al. International Parkinson and Movement\nDisorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor\nSymptoms of Parkinson’s Disease. Movement Disorders. 2018.\nProgram Prior Authorization/Medical Necessity – Nourianz (istradefylline)\nChange Control\n12/2019 New program\n12/2020 Annual review. Updated references.\n12/2021 Annual review. Updated references.\n12/2022 Annual review. Updated references.\n12/2023 Annual review. Updated references.\n12/2024 Annual review. Updated initial authorization to 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}